Once-Daily (od) Fluticasone Furoate/vilanterol (ff/vi: 100/25mcg) Compared With Twice-Daily (bd) Fluticasone Propionate/salmeterol (fsc: 250/50mcg) In Patients With COPD

被引：0
|
作者：
Dransfield, M. T. [1 ]
Crim, C. C. [2 ]
Feldman, G. [3 ]
Korenblat, P. E. [4 ]
Laforce, C. [5 ]
Locantore, N. [2 ]
Pistolesi, M. [6 ]
Watkins, M. [2 ]
Martinez, F. J. [7 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] GlaxoSmithKline, Reseach Triangle Pk, NC USA
[3] South Carolina Pharmaceut Res, Spartanburg, SC USA
[4] Clin Res Ctr LLC, St Louis, MO USA
[5] Carolina Allergy & Asthma, Cary, NC USA
[6] Univ Florence, Florence, Italy
[7] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2432
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroub of Patients from China with Symptomatic COPO at Risk of Exacerbations (FULFIL Trial)
    Zheng, Jinping
    Zhong, Nanshan
    Wang, Changzheng
    Huan, Yijiang
    Chen, Ping
    Wang, Limin
    Hui, Fuxin
    Zhao, Li
    Wang, Haoyan
    Luo, Linda
    Du, Xin
    Goh, Aik Han
    Lipson, David A.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 15 (04) : 334 - 340
  • [42] EFFECT OF ONCE-DAILY SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL TRIPLE THERAPY ON SEVERE EXACERBATION RATES COMPARED WITH TWICE-DAILY BUDESONIDE/FORMOTEROL DUAL THERAPY IN PATIENTS WITH COPD: A POST HOC ANALYSIS OF THE FULFIL STUDY
    Panettieri, Reynold
    Bangalore, Mohan
    Camargo, Carlos
    Cheema, Tariq
    El Bayadi, Sherif
    Fiel, Stanley
    Jain, Renu
    Midwinter, Dawn
    Rabadi, Nashat
    Thomashow, Byron
    Lipson, David
    CHEST, 2021, 160 (04) : 1818A - 1821A
  • [43] Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial
    Devillier, Philippe
    Humbert, Marc
    Boye, Alain
    Zachgo, Wolfgang
    Jacques, Loretta
    Nunn, Carol
    West, Sarah
    Nicholls, Andy
    Antoun, Zeina
    Spinu, Luminita
    Grouin, Jean-Marie
    RESPIRATORY MEDICINE, 2018, 141 : 111 - 120
  • [44] Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)
    Gessner, Christian
    Kornmann, Oliver
    Maspero, Jorge
    van Zyl-Smit, Richard
    Kruell, Matthias
    Salina, Anna
    Gupta, Pritam
    Bostel, Sebastien
    Fucile, Sebastian
    Conde, Lorena Garcia
    Pfister, Pascal
    RESPIRATORY MEDICINE, 2020, 170
  • [45] ONCE-DAILY INDACATEROL/GLYCOPYRRONIUM (IND/GLY) IS MORE EFFECTIVE THAN TWICE-DAILY SALMETEROL/FLUTICASONE (SFC) IN REDUCING EXACERBATIONS IN COPD PATIENTS AT A HIGH RISK OF EXACERBATIONS: THE FLAME STUDY
    Wedzicha, J. A.
    Chapman, K. R.
    Larbig, M.
    Patalano, F.
    Thach, C.
    Fogel, R.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 116 - 116
  • [46] Once-Daily Qva149 Is More Effective Than Twice-Daily Salmeterol/fluticasone In Improving Lung Function, In Patients With Severe Chronic Obstructive Pulmonary Disease (COPD): The Illuminate Study
    Vogelmeier, C.
    Bateman, E. D.
    D'Andrea, P.
    Mezzi, K.
    Chen, H.
    Banerji, D.
    Fogel, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [47] Once-Daily Indacaterol/glycopyrronium Reduces The Rate And Risk Of Moderate Or Severe Exacerbations Compared With Twice-Daily Salmeterol/fluticasone In A Subset Of Gold Group D COPD Patients With A History Of ≥2 Exacerbations Or 1 Hospitalization: The Flame Study
    Vogelmeier, C.
    Wedzicha, J.
    Donohue, J.
    Fucile, S.
    Yadao, A.
    Ayers, T.
    Thach, C.
    Taylor, A. Fowler
    Fogel, R.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [48] REDUCTION IN THE RATE AND RISK OF MODERATE OR SEVERE EXACERBATIONS WITH ONCE-DAILY INDACATEROL/GLYCOPYRRONIUM COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE IN A SUBSET OF GOLD GROUP D COPD PATIENTS WITH A HISTORY OF ≥2 EXACERBATIONS OR 1 HOSPITALIZATION: THE FLAME STUDY
    Banerji, D.
    Vogelmeier, C.
    Wedzicha, J.
    Donohue, J.
    Fucile, S.
    Yadao, A.
    Ayers, T.
    Thach, C.
    Olsson, P.
    Fowlertaylor, A.
    Fogel, R.
    Patalano, F.
    RESPIROLOGY, 2018, 23 : 74 - 74
  • [49] Fixed-dose combination of indacaterol/glycopyrronium/ mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON) (vol 170, 106021, 2020)
    Gessner, Christian
    Kornmann, Oliver
    Maspero, Jorge
    van Zyl-Smit, Richard
    Kruell, Matthias
    Salina, Anna
    Gupta, Pritam
    Bostel, Sebastien
    Fucile, Sebastian
    Conde, Lorena Garcia
    Pfister, Pascal
    RESPIRATORY MEDICINE, 2020, 175
  • [50] Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study
    Fogel, Robert
    Chapman, Kenneth R.
    Vogelmeier, Claus F.
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Whelan, Sarah
    Clerkin, Karyn
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345